Efficacy and Safety of Patiromer in Hyperkalemia: A Systematic Review and Meta-Analysis:

Background:Patients at the highest risk of hyperkalemia are those with chronic kidney disease (CKD) stages 3 and 4.Objective:To evaluate the efficacy and safety of patiromer in hyperkalemia in patients with heart failure or CKD.Methods:The Cochrane Renal Group’s Specialized Register was searched through contact with the Trials’ Search Coordinator. We aimed at including randomized controlled trials with patiromer in patients with developed or risks of developing hyperkalemia, comparing against an active comparator or placebo. Three studies matched our inclusion and exclusion criteria, which we included in the meta-analysis. All-cause mortality, reduction in hospitalization, episodes of hypokalemia or hyperkalemia, and cardiovascular and gastrointestinal adverse events during the treatment period were our primary outcomes. Serial change in serum potassium (K+) until end of treatment or follow-up during the trial period and all other reported adverse reactions during the treatment period were our secondary o...